A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide: Induction Phase: Chidamide 15 mg orally on days 1, 4, 8, 11, 15, and 18 of each 21-day cycle for 4 cycles.PD-L1 inhibitor, carboplatin, and etoposide are administered per their respective prescribing information.
Maintenance Phase: Chidamide 20 mg orally twice weekly (at least 3 days apart) until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.PD-L1 inhibitor is administered per their respective prescribing information.
Study summary
This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients. The primary objective is to assess Progression-Free Survival (PFS) per RECIST v1.1. Secondary objectives include Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), and safety. Approximately 36 participants will receive induction therapy (Chidamide + chemotherapy + PD-L1 inhibitor) for 4 cycles, followed by Chidamide maintenance until progression or unacceptable toxicity.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 and ≤75 years.
* Histologically confirmed ES-SCLC, unsuitable for local radical therapy.
* No prior systemic therapy for ES-SCLC.
* ECOG performance status 0-1.
* At least one measurable lesion per RECIST v1.1.
* Expected survival ≥3 months.
* Adequate organ function (hematological, hepatic, renal, cardiac).
* Effective contraception from consent until 180 days after last dose.
* For active HBV infection: HBV DNA \<2000 IU/mL within 28 days before treatment and on stable antiviral therapy.
* Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).
* Signed informed consent.
Exclusion Criteria:
* Factors significantly affecting oral drug absorption.
* Prior HDAC inhibitor or immune checkpoint inhibitor therapy.
* Known allergy to any study drug component.
* Other malignancy within past 5 years (except certain cured cancers).
* Participation in another clinical trial within 4 weeks.
* Immunodeficiency, HIV positivity, or organ transplant history.
* Uncontrolled cardiovascular disease or QTc \>450 ms.
* Pregnancy, lactation, or unwillingness to use effective contraception.
* Other severe comorbid conditions deemed unsafe by investigator.
* History of neurological or psychiatric disorders.
* Any condition making the patient unsuitable per investigator judgment.
Primary outcome measure(s)
Progression-Free Survival (PFS) per RECIST v1.1 as assessed by the investigator. — baseline up to approximately 24 months
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of China Medical University
Shenyang
Liaoning
Recruiting
More China Medical University, China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.